Savara (SVRA) announced the European Patent Office has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.” The patent is jointly held by Savara and Pari and covers the combination of Savara’s investigational therapy, Molbreevi and Pari’s investigational eFlow Nebulizer System that has been optimized for the delivery of Molbreevi.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
- Savara Inc. Reports Q3 2025 Financial Results
- Savara price target raised to $9 from $8 at Oppenheimer
- Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
- Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential